CUMBERLAND PHARMACEUTICALS INC Q1 FY2025 earnings call

Financial Results - Combined revenues of FDA-approved brands were $11.7 million, a 38% increase over prior year. - Net profit was $1.26 million, adjusted earnings $2.4 million, and cash flow from operations $3.9 million. - A $3 million milestone payment from Vibativ's China approval bolstered financials. ### Product Updates - Vibativ approved in China, with launch expected later this year. - Ifetroban Phase II study in DMD showed positive results, first successful for cardiac complications, with next steps including FDA meeting. - Spring national sales meeting in March launched new marketing initiatives; sales teams across 3 divisions support FDA-approved products. - Kristalose performing well in Medicaid-covered states, with marketing updates and specialty distribution partnership. - Caldolor's pediatric labeling cleared, growing use in children's hospitals. - Sancuso seeing favorable sales, with revised sampling program and enhanced patient support. - Vaprisol's new manufacturing partner working to address FDA issues for future approval.

For the first quarter of 2025, net revenue from continuing operations was $11.7 million, a 38% increase over the prior year period. Net revenue by product included $3.5 million for Kristalose, $2.3 million for Sancuso, $1.4 million for Vibativ, and $1.3 million for Caldolor. Kristalose contributed approximately 29.9% to total net revenue, Sancuso around 19.7%, Vibativ about 11.9%, and Caldolor roughly 11.1%.

- Expect continued momentum across approved brands. - Anticipate further progress and milestones in clinical pipeline. - Look forward to new opportunities through targeted acquisitions.

• Factors such as natural disasters, economic downturns, public health epidemics, international conflicts, and trade restrictions that could affect future results. These are described in the company's Form 10-K and SEC filings.